{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=atezolizumab&page=4", "query": { "intervention": "atezolizumab", "page": 4 }, "page_size": 10 }, "pagination": { "page": 4, "page_size": 10, "total_count": 512, "total_pages": 52, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=atezolizumab&page=5&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=atezolizumab&page=3&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-12T14:01:43.258Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03853707", "title": "Ipatasertib in Combination With Carboplatin, Carboplatin/Paclitaxel, or Capecitabine/Atezolizumab in Treating Patients With Metastatic Triple Negative Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Anatomic Stage IV Breast Cancer AJCC v8", "Metastatic Triple-Negative Breast Carcinoma", "Prognostic Stage IV Breast Cancer AJCC v8" ], "interventions": [ { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Ipatasertib", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 28, "start_date": "2019-03-04", "completion_date": "2023-09-19", "has_results": true, "last_update_posted_date": "2024-02-20", "last_synced_at": "2026-10-12T14:01:43.258Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03853707" }, { "nct_id": "NCT02792192", "title": "Safety and Pharmacology Study of Atezolizumab Alone and in Combination With Bacille Calmette-Guérin (BCG) in High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) Participants", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Bladder Cancer" ], "interventions": [ { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Bacille Calmette-Guérin", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2016-06-13", "completion_date": "2020-09-29", "has_results": true, "last_update_posted_date": "2021-10-28", "last_synced_at": "2026-10-12T14:01:43.258Z", "location_count": 8, "location_summary": "Stanford, California • Chicago, Illinois • Baltimore, Maryland + 5 more", "locations": [ { "city": "Stanford", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "The Bronx", "state": "New York" }, { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT02792192" }, { "nct_id": "NCT04504669", "title": "First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Clear Cell Renal Cell Cancer", "Non-Small-Cell Lung Cancer", "Triple Negative Breast Neoplasms", "Squamous Cell Cancer of Head and Neck", "Small Cell Lung Cancer", "Gastroesophageal Cancer", "Melanoma", "Cervical Cancer", "Advanced Solid Tumours" ], "interventions": [ { "name": "AZD8701", "type": "DRUG" }, { "name": "Durvalumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "101 Years", "sex": "ALL", "summary": "18 Years to 101 Years" }, "enrollment_count": 60, "start_date": "2020-08-18", "completion_date": "2024-10-07", "has_results": false, "last_update_posted_date": "2024-11-05", "last_synced_at": "2026-10-12T14:01:43.258Z", "location_count": 6, "location_summary": "Baltimore, Maryland • St Louis, Missouri • Huntersville, North Carolina + 3 more", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Huntersville", "state": "North Carolina" }, { "city": "Franklin", "state": "Tennessee" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04504669" }, { "nct_id": "NCT02609984", "title": "Study to Compare the Safety and Efficacy of CMB305 With Atezolizumab to Atezolizumab Alone in Participants With Sarcoma (IMDZ-C232/V943A-002)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Sarcoma", "Myxoid/Round Cell Liposarcoma", "Synovial Sarcoma", "Metastatic Sarcoma", "Recurrent Adult Soft Tissue Sarcoma", "Locally Advanced Sarcoma", "Liposarcoma" ], "interventions": [ { "name": "CMB305", "type": "BIOLOGICAL" }, { "name": "atezolizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 89, "start_date": "2015-04-29", "completion_date": "2019-02-06", "has_results": true, "last_update_posted_date": "2020-07-07", "last_synced_at": "2026-10-12T14:01:43.258Z", "location_count": 18, "location_summary": "Palo Alto, California • Santa Monica, California • Aurora, Colorado + 15 more", "locations": [ { "city": "Palo Alto", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02609984" }, { "nct_id": "NCT06921785", "title": "Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hepatocellular Carcinoma" ], "interventions": [ { "name": "Tremelimumab", "type": "DRUG" }, { "name": "Rilvegostomig", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Atezolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1220, "start_date": "2025-05-06", "completion_date": "2030-03-15", "has_results": false, "last_update_posted_date": "2026-09-03", "last_synced_at": "2026-10-12T14:01:43.258Z", "location_count": 36, "location_summary": "Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 30 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT06921785" }, { "nct_id": "NCT07235293", "title": "A Study to Test DSP107 in Combination With Atezolizumab in Comparison With Fruquintinib as a New Treatment for Colorectal Cancer.", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Colorectal Cancer" ], "interventions": [ { "name": "DSP107 + Atezolizumab", "type": "DRUG" }, { "name": "Fruquintinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Kahr Bio Australia Pty Ltd", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 90, "start_date": "2026-01-16", "completion_date": "2027-04-30", "has_results": false, "last_update_posted_date": "2026-08-20", "last_synced_at": "2026-10-12T14:01:43.258Z", "location_count": 6, "location_summary": "Aurora, Colorado • Highlands Ranch, Colorado • Florida City, Florida + 3 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Highlands Ranch", "state": "Colorado" }, { "city": "Florida City", "state": "Florida" }, { "city": "Durham", "state": "North Carolina" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT07235293" }, { "nct_id": "NCT04710498", "title": "Neoadjuvant Atezolizumab in Surgically Resectable Advanced Cutaneous Squamous Cell Carcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cutaneous Squamous Cell Carcinoma" ], "interventions": [ { "name": "Atezolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Stanford University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2021-06-22", "completion_date": "2024-02-15", "has_results": true, "last_update_posted_date": "2025-02-03", "last_synced_at": "2026-10-12T14:01:43.258Z", "location_count": 1, "location_summary": "Stanford, California", "locations": [ { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04710498" }, { "nct_id": "NCT06807632", "title": "A Study of Valemetostat in Combination With Atezolizumab in People With Lung Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Extensive-stage Small-cell Lung Cancer" ], "interventions": [ { "name": "Valemetostat", "type": "DRUG" }, { "name": "Atezolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2025-01-29", "completion_date": "2027-01", "has_results": false, "last_update_posted_date": "2026-08-11", "last_synced_at": "2026-10-12T14:01:43.258Z", "location_count": 7, "location_summary": "Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more", "locations": [ { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Montvale", "state": "New Jersey" }, { "city": "Commack", "state": "New York" }, { "city": "Harrison", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06807632" }, { "nct_id": "NCT02463994", "title": "A Pilot Study of MPDL3280A and HIGRT in Metastatic NSCLC", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Non-small Cell Lung Cancer" ], "interventions": [ { "name": "MPDL3280A", "type": "DRUG" }, { "name": "Hypofractionated Radiotherapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "University of Michigan Rogel Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2015-10", "completion_date": "2018-11-07", "has_results": false, "last_update_posted_date": "2019-02-08", "last_synced_at": "2026-10-12T14:01:43.258Z", "location_count": 2, "location_summary": "Ann Arbor, Michigan • Seattle, Washington", "locations": [ { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT02463994" }, { "nct_id": "NCT05019703", "title": "Atezolizumab and Cabozantinib for the Treatment of Adolescents and Young Adults With Recurrent or Metastatic Osteosarcoma, TACOS Study", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Locally Advanced Osteosarcoma", "Metastatic Osteosarcoma", "Recurrent Osteosarcoma", "Refractory Osteosarcoma", "Unresectable Osteosarcoma" ], "interventions": [ { "name": "Atezolizumab", "type": "BIOLOGICAL" }, { "name": "Cabozantinib", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 40, "start_date": "2023-04-25", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-10-06", "last_synced_at": "2026-10-12T14:01:43.258Z", "location_count": 2, "location_summary": "Boston, Massachusetts • Houston, Texas", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05019703" } ] }